{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:24:02Z","timestamp":1778815442096,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40272-024-00645-7","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T11:02:57Z","timestamp":1722855777000},"page":"741-752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5431-3979","authenticated-orcid":false,"given":"Ilina C.","family":"Odouard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeromie","family":"Ballreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branden","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana P.","family":"Socal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"645_CR1","unstructured":"Food & Drug Administration (FDA). What is Gene Therapy? 2018. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/what-gene-therapy. Accessed 15 Aug 2023."},{"key":"645_CR2","unstructured":"American Society of Cell and Gene Therapy. Gene, cell, and rna therapy landscape|Q1 2023 quarterly data report. American Society of Cell and Gene Therapy. 2023. https:\/\/asgct.org\/global\/documents\/asgct-citeline-q1-2023-report.aspx. Accessed 28 Feb 2024."},{"key":"645_CR3","unstructured":"Food & Drug Administration (FDA). Considerations for the design of early-phase clinical trials of cellular and gene therapy products: guidance for industry. Food & Drug Administration (FDA). 2015. https:\/\/www.fda.gov\/media\/106369\/download. Accessed 23 Apr 2024."},{"issue":"1","key":"645_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29(1):49\u201358.","journal-title":"Nat Med"},{"key":"645_CR5","unstructured":"Food & Drug Administration (FDA). Demonstrating substantial evidence of effectiveness for human drug and biological products guidance for industry. 2019. https:\/\/www.fda.gov\/media\/133660\/download. Accessed 15 Sept 2023."},{"key":"645_CR6","unstructured":"George J. Controversial gene therapy wins FDA approval for duchenne muscular dystrophy. MedPage Today. 2023. https:\/\/www.medpagetoday.com\/neurology\/generalneurology\/105143. Accessed 15 Aug 2023."},{"issue":"1","key":"645_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/cer-2017-0068","volume":"7","author":"G Hampson","year":"2018","unstructured":"Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US Health Care System. J Comp Eff Res. 2018;7(1):15\u201328.","journal-title":"J Comp Eff Res."},{"issue":"7","key":"645_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eclinm.2019.01.015","volume":"7","author":"M Abou-El-Enein","year":"2019","unstructured":"Abou-El-Enein M, Hey SP. Cell and gene therapy trials: are we facing an \u2018evidence crisis\u2019? EClinicalMedicine. 2019;7(7):13\u20134.","journal-title":"EClinicalMedicine."},{"issue":"10","key":"645_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.773629","volume":"10","author":"T Qiu","year":"2022","unstructured":"Qiu T, Pochopien M, Liang S, et al. Gene therapy evidence generation and economic analysis: pragmatic considerations to facilitate fit-for-purpose health technology assessment. Front Public Health. 2022;10(10): 773629.","journal-title":"Front Public Health"},{"issue":"7","key":"645_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/MLR.0000000000001840","volume":"61","author":"B Ghanem","year":"2023","unstructured":"Ghanem B, Seoane-Vazquez E, Brown L, Rodriguez-Monguio R. Analysis of the gene therapies authorized by the United States Food and Drug Administration and the European Medicines Agency. Med Care. 2023;61(7):438\u201347.","journal-title":"Med Care"},{"issue":"11","key":"645_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4115","volume":"3","author":"RE Sachs","year":"2022","unstructured":"Sachs RE, Donohue JM, Dusetzina SB. Reforming reimbursement for the US Food and Drug Administration\u2019s accelerated approval program to support state medicaid programs. JAMA Health Forum. 2022;3(11): e224115.","journal-title":"JAMA Health Forum."},{"issue":"18","key":"645_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.2020.19325","volume":"324","author":"RE Sachs","year":"2020","unstructured":"Sachs RE, Donohue JM, Dusetzina SB. Confronting state medicaid drug spending pressures. JAMA J Am Med Assoc. 2020;324(18):1831\u20132.","journal-title":"JAMA J Am Med Assoc"},{"key":"645_CR13","unstructured":"Food and Drug Administration (FDA). Accelerated approval program. 2023. https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/accelerated-approval-program. Accessed 15 Sept 2023."},{"key":"645_CR14","unstructured":"Bayer M. The future of accelerated approval for FDA\u2019s Marks? More rare disease drugs and no \u2018hanging chads\u2019. Fierce Biotech Web site. https:\/\/www.fiercebiotech.com\/biotech\/peter-marks-says-fda-now-has-better-sense-rare-disease-biomarkers-will-more-accelerated. Updated 2023. Accessed 27 Oct 2023."},{"issue":"2","key":"645_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","volume":"323","author":"JJ Darrow","year":"2020","unstructured":"Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983\u20132018. JAMA. 2020;323(2):164\u201376.","journal-title":"JAMA"},{"key":"645_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2020.104144","volume":"139","author":"A Daei","year":"2020","unstructured":"Daei A, Soleymani MR, Ashrafi-rizi H, Zargham-Boroujeni A, Kelishadi R. Clinical information seeking behavior of physicians: a systematic review. Int J Med Inform (Shannon, Ireland). 2020;139: 104144.","journal-title":"Int J Med Inform (Shannon, Ireland)."},{"issue":"9","key":"645_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1001\/jamainternmed.2014.3438","volume":"174","author":"JW Smithy","year":"2014","unstructured":"Smithy JW, Downing NS, Ross JS. Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study. JAMA Intern Med. 2014;174(9):1518\u201320.","journal-title":"JAMA Intern Med"},{"issue":"5 Spec No.","key":"645_CR18","first-page":"SP71","volume":"18","author":"A Wang","year":"2012","unstructured":"Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. US Payer perspectives on evidence for formulary decision making. Am J Manag Care. 2012;18(5 Spec No.):SP71\u20136.","journal-title":"Am J Manag Care"},{"key":"645_CR19","unstructured":"Centers for Medicare and Medicaid Services. Who Enrolls in Medicaid and CHIP? Medicaid.Gov. https:\/\/www.medicaid.gov\/state-overviews\/scorecard\/who-enrolls-medicaid-chip\/index.html. Accessed 15 Aug 2023."},{"issue":"8","key":"645_CR20","first-page":"1108","volume":"180","author":"T Hilal","year":"2020","unstructured":"Hilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. Arch Intern Med (1960). 2020;180(8):1108\u201315.","journal-title":"Arch Intern Med (1960)"},{"issue":"4","key":"645_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/jama.2013.282542","volume":"311","author":"LV Sacks","year":"2014","unstructured":"Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000\u20132012. JAMA. 2014;311(4):378\u201384.","journal-title":"JAMA"},{"issue":"4","key":"645_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","volume":"24","author":"JJ Darrow","year":"2019","unstructured":"Darrow JJ. Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today. 2019;24(4):949\u201354.","journal-title":"Drug Discov Today"},{"key":"645_CR23","unstructured":"Food and Drug Administration (FDA). Approved cellular and gene therapy products. 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products Accessed 15 Aug 2023."},{"key":"645_CR24","unstructured":"Food and Drug Administration (FDA). New drugs at FDA: CDER\u2019s new molecular entities and new therapeutic biological products. 2023. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products Accessed 15 Aug 2023."},{"key":"645_CR25","unstructured":"Food and Drug Administration. Drugs@FDA: FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 6 July 2023."},{"key":"645_CR26","unstructured":"Kothadia JP, LaFreniere K, Shah JM. Acute Hepatic Porphyria [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537178\/."},{"issue":"6","key":"645_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ejh.13512","volume":"105","author":"A Kattamis","year":"2020","unstructured":"Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of beta-thalassemia. Eur J Haematol. 2020;105(6):692\u2013703.","journal-title":"Eur J Haematol"},{"issue":"11","key":"645_CR28","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1136\/bjophthalmol-2018-313089","volume":"103","author":"A Lloyd","year":"2019","unstructured":"Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. 2019;103(11):1610\u20134.","journal-title":"Br J Ophthalmol"},{"key":"645_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/CCID.S232547","volume":"12","author":"S Eichstadt","year":"2019","unstructured":"Eichstadt S, Tang JY, Solis DC, et al. From clinical phenotype to genotypic modelling: incidence and prevalence of recessive dystrophic epidermolysis bullosa (RDEB). Clin Cosmet Investig Dermatol. 2019;12:933\u201342.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"645_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13998","volume":"26","author":"JM Soucie","year":"2020","unstructured":"Soucie JM, Miller CH, Dupervil B, Le B, Buckner TW. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia. 2020;26(3):487\u201393.","journal-title":"Haemophilia"},{"key":"645_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.703305","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang X, Danese D, Brown T, et al. Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study. Front Med. 2021;8: 703305.","journal-title":"Front Med"},{"issue":"1","key":"645_CR32","doi-asserted-by":"publisher","first-page":"017","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):017\u201323.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"645_CR33","doi-asserted-by":"publisher","first-page":"020","DOI":"10.1186\/s13023-020-01623-1","volume":"16","author":"M Vera-Llonch","year":"2021","unstructured":"Vera-Llonch M, Reddy SR, Chang E, Tarbox MH, Pollock M. The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis. Orphanet J Rare Dis. 2021;16(1):020\u20131.","journal-title":"Orphanet J Rare Dis"},{"key":"645_CR34","unstructured":"Raymond GV, Moser AB, Fatemi A. X-Linked adrenoleukodystrophy. In: Adam MP, Feldman J, Mirzaa GM, et al, editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993."},{"issue":"1","key":"645_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"key":"645_CR36","doi-asserted-by":"crossref","unstructured":"UpToDate. Wolters Kluwer Website. https:\/\/www.wolterskluwer.com\/en\/solutions\/uptodate. Accessed 11 Aug 2023.","DOI":"10.1097\/01.NPR.0000000000000050"},{"key":"645_CR37","unstructured":"NAVLIN, EVERSANA\u2019s global pricing and market access database. https:\/\/data.navlin.com\/alspc\/#!\/. Updated 2023. Accessed 7 Aug 2023."},{"key":"645_CR38","unstructured":"US Food and Drug Administration. Search orphan drug designations and approvals. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm. Accessed 11 Aug 2023."},{"key":"645_CR39","unstructured":"Food & Drug Administration (FDA). Table of surrogate endpoints that were the basis of drug approval or licensure. Food and Drug Administration (FDA) website. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Updated 2022. Accessed 25 Aug 2023."},{"issue":"7","key":"645_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1718","volume":"4","author":"CJR Daval","year":"2023","unstructured":"Daval CJR, Teng TW, Russo M, Kesselheim AS. Association of advisory committee votes with US Food and Drug Administration decision-making on prescription drugs, 2010\u20132021. JAMA Health Forum. 2023;4(7): e231718.","journal-title":"JAMA Health Forum."},{"issue":"7","key":"645_CR41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.7326\/M21-4442","volume":"175","author":"J Ballreich","year":"2022","unstructured":"Ballreich J, Socal M, Bennett CL, et al. Medicare spending on drugs with accelerated approval. Ann Intern Med. 2022;175(7):938\u201344.","journal-title":"Ann Intern Med"},{"issue":"6","key":"645_CR42","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","volume":"4","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018;4(6):849\u201356.","journal-title":"JAMA Oncol"},{"issue":"7","key":"645_CR43","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2018.0610","volume":"4","author":"M Zettler","year":"2018","unstructured":"Zettler M, Nabhan C. Fulfillment of postmarketing requirements to the FDA for therapies granted oncology indications between 2011 and 2016. JAMA Oncol. 2018;4(7):993\u20134.","journal-title":"JAMA Oncol"},{"key":"645_CR44","unstructured":"Meglio M. SRP-9001 fails to meet primary end point in phase 3 EMBARK study. NeurologyLive. 2023. https:\/\/www.neurologylive.com\/view\/srp-9001-fails-to-meet-primary-end-point-phase-3-embark-study Accessed 19 Jan 2024."},{"issue":"7","key":"645_CR45","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","volume":"318","author":"H Naci","year":"2017","unstructured":"Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA J Am Med Assoc. 2017;318(7):626\u201336.","journal-title":"JAMA J Am Med Assoc"},{"issue":"11","key":"645_CR46","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"3","key":"645_CR47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jval.2017.08.3013","volume":"21","author":"DC Malone","year":"2018","unstructured":"Malone DC, Brown M, Hurwitz JT, Peters L, Graff JS. Real-world evidence: useful in the real world of US payer decision making? How? when? and What Studies? Value Health. 2018;21(3):326\u201333.","journal-title":"Value Health."},{"issue":"9","key":"645_CR48","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1111\/bcp.14284","volume":"86","author":"TB Polak","year":"2020","unstructured":"Polak TB, Rosmalen J, Uyl-de Groot CA. Expanded access as a source of real-world data: an overview of FDA and EMA approvals. Br J Clin Pharmacol. 2020;86(9):1819\u201326.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"645_CR49","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/1468-0009.12413","volume":"97","author":"M Herder","year":"2019","unstructured":"Herder M. Pharmaceutical drugs of uncertain value, lifecycle regulation at the US Food and Drug Administration, and institutional incumbency. Milbank Q. 2019;97(3):820\u201357.","journal-title":"Milbank Q"},{"issue":"4","key":"645_CR50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/rme-2020-0169","volume":"16","author":"J J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16(4):405\u201322.","journal-title":"Regen Med"},{"issue":"14","key":"645_CR51","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.2023.17131","volume":"330","author":"IC Odouard","year":"2023","unstructured":"Odouard IC, Socal MP, Anderson GF. Role of registries in medicare coverage of new alzheimer disease drugs. JAMA J Am Med Assoc. 2023;330(14):1331\u20132.","journal-title":"JAMA J Am Med Assoc"},{"issue":"4","key":"645_CR52","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","volume":"311","author":"NS Downing","year":"2014","unstructured":"Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005\u20132012. JAMA. 2014;311(4):368\u201377.","journal-title":"JAMA"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00645-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T15:04:25Z","timestamp":1730127865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00645-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00645-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"15 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Arnold Ventures. The funder had no role in formulation of the research question, study design, study conduct, interpretation, manuscript development, or decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ms. Odouard, Dr. Ballreich, and Dr. Socal received research grants from Arnold Ventures. Ms. Odouard was previously employed as a consultant at life sciences and healthcare consulting firms Blue Matter Consulting and Health Technology Analysts. Mr. Lee declares that he has no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"All data generated or analyzed during this study are included in this published article and the online supplement.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availabability"}},{"value":"Ms. Odouard, Dr. Ballreich, and Dr. Socal contributed to the study conception and design. Material preparation and data collection were performed by Ms. Odouard and Mr. Lee. All authors participated in analysis and interpretation of the results. The first draft of the manuscript was written by Ms. Odouard, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}